Equities

SymBio Pharmaceuticals Ltd

SymBio Pharmaceuticals Ltd

Actions
  • Price (USD)1.21
  • Today's Change0.00 / 0.00%
  • Shares traded20.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Aug 21 2024 19:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Income statement Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 202320232022
REVENUE AND GROSS PROFIT
Total revenue5,59010,008
OPERATING EXPENSES
Cost of revenue total1,1792,408
Selling, general and admin. expenses, total2,5843,009
Depreciation/amortization--72
Unusual expense(income)492(106)
Other operating expenses, total0.000.00
Total operating expense6,8947,938
Operating income(1304)2,070
Other, net(20)(100)
INCOME TAXES, MINORITY INTEREST AND EXTRA ITEMS
Net income before taxes(1195)2,106
Provision for income taxes767927
Net income after taxes(1963)1,179
Minority interest----
Net income before extra. Items(1963)1,179
Total extraordinary items----
Net income(1963)1,179
Inc.avail. to common excl. extra. Items(1963)1,179
Inc.avail. to common incl. extra. Items(1963)1,179
EPS RECONCILIATION
Basic/primary weighted average shares4039
Basic/primary eps excl. extra items(49)30
Basic/primary eps incl. extra items(49)30
Dilution adjustment----
Diluted weighted average shares4040
Diluted eps excl. extra items(49)30
Diluted eps incl. extra items(49)30
COMMON STOCK DIVIDENDS
DPS - common stock primary issue----
Gross dividend - common stock00
PRO FORMA INCOME
Pro forma net income----
Interest expense, supplemental----
SUPPLEMENTAL INCOME
Depreciation, supplemental9698
Total special items492(106)
NORMALISED INCOME
Normalized income before taxes(703)2,000
Effect of special items on income taxes172(47)
Income tax excluding impact of special items940880
Normalized income after tax(1643)1,120
Normalized income avail. to common(1643)1,120
Basic normalized EPS(41)29
Diluted normalized EPS(41)28
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.